Navigation Links
Tarantula venom-based MD therapy to be advanced by UB scientists' biotech company
Date:12/29/2009

dminister the drug. The peptide and its mirror image are covered by U.S. patents obtained by UB's Office of Science, Technology Transfer and Economic Outreach (STOR), and licensed to Rose Pharmaceuticals. Sachs noted that there are no other drugs known to act specifically on mechanosensitive ion channels, the target of GsMTx4.

"Unlike most drugs, GsMTx4 seems to generate only positive side effects," said Sachs. "In addition to its effectiveness in MD, it inhibits atrial fibrillation, a cardiac arrhythmia that affects 2 million Americans, and for which there currently is no reliable drug therapy.

"In a second application, research groups in Korea and UC San Francisco have shown that GsMTx4 can inhibit mechanically induced pain (pain originating in nerve fibers)," he said. "This therapy is at least half as effective as morphine, but does not act on the brain, only at the site of increased sensitivity." Mark Kristal, PhD, UB professor of psychology, has been collaborating on the pain testing.

GsMTx4 appears to have additional applications. Robert Plunkett, MD., UB associate professor of neurosurgery, has shown that the peptide stimulates neuronal growth, and may be useful for the treatment of Parkinson's disease.


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-4606
University at Buffalo
Source:Eurekalert

Page: 1 2

Related biology news :

1. Successful stem cell therapy for treatment of eye disease
2. Gene therapy and stem cells save limb
3. New therapy targets for amyloid disease
4. New understanding about mechanism for cell death after stroke leads to possible therapy
5. Duke develops nano-scale drug delivery for chemotherapy
6. Caltech researchers show efficacy of gene therapy in mouse models of Huntingtons disease
7. USU scientists report major advance in human antibody therapy against deadly Nipah virus
8. Patients in Europe benefit from new radiation therapy
9. LX211 highlighted as potential disease modifying therapy for non-infectious uveitis
10. Research needed to learn which DCIS patients may be candidates for less invasive therapy
11. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... + Lomb, the global eye health company, announced today that ... unowned shares of Technolas ™ Perfect Vision GmbH (TPV), ... was established in 2009 through a joint venture between Bausch ... sell advanced refractive and cataract technologies. The deal is expected ...
... -- Four innovating life science fields to keep an ... and tissue culture. Thanks to an aging population and ... these markets are on the rise. (Photo: ... (GII) presents four innovative life science market research reports ...
... . , Methane is formed under the absence ... the sea floor. It is a much more powerful greenhouse ... this gas is inactivated before it reaches the atmosphere and ... have now proven that these microorganisms are quite picky about ...
Cached Biology News:Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 2Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 3Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 2Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 3Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 4Strange diet for methane consuming microorganisms 2
(Date:12/24/2014)... Md. , Dec. 24, 2014  United ... today that Medtronic, Inc. (NYSE: MDT ... the U.S. Food and Drug Administration (FDA) for ... implantable drug infusion system (including a newly developed ... (treprostinil) Injection delivered intravenously to patients with ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... iKnowMed™, the US Oncology ... vendors selected to participate in the fourth American Society of ... June 5-7 at the 2010 ASCO Annual Meeting ... company uniting the nation,s largest network of community-based oncologists, will ...
... , MENLO PARK, Calif. and KANNAPOLIS, N.C. ... Inc. (ITI) and the David H. Murdock Research Institute (DHMRI) ... Path Research in Immunology (CCPRI) at The David H. Murdock ... Kannapolis, NC . Driven by a mission to accelerate the ...
... , , , ... Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction , ... Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a,developer ... the safety and pharmacodynamics,of five oral insulin formulations in healthy subjects," authored by Dr. ...
Cached Biology Technology:US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 2US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 3US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 4US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 5The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 2The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 3Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 2Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 3
Request Info...
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Validated and Silencer Pre-designed siRNAs, which are ...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: